News & Updates
Filter by Specialty:
Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC
Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.
Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC
20 Jan 2023
TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients
Tumour necrosis factor (TNF)-α antagonists show comparable safety as non-TNF biologics in the treatment of inflammatory bowel disease (IBD) in patients with active or recent cancer, as shown in a study.
TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients
20 Jan 2023
Can RA patients taper MTX from targeted therapy?
A recent study has found that tapering methotrexate (MTX) from targeted therapy in patients with controlled rheumatoid arthritis (RA) is feasible, but this may result in a 10-percent decrease in the ability to sustain remission for up to 18 months.
Can RA patients taper MTX from targeted therapy?
18 Jan 2023
Fluvoxamine strikes out in mild-to-moderate COVID-19
Treatment with fluvoxamine does not appear to improve outcomes in patients with mild-to-moderate COVID-19, with a study showing that the drug does not shorten symptom duration as compared with placebo.
Fluvoxamine strikes out in mild-to-moderate COVID-19
18 Jan 2023
Artificial pancreas yields good results in type 2 diabetes patients
A fully closed-loop insulin delivery system, also known as artificial pancreas, helps improve the management of type 2 diabetes in adults, increasing the time spent in target glucose range by 8 hours per day without promoting hypoglycaemic events as compared with standard insulin therapy, as reported in a study.
